Strategies for Combating Opioid-Induced Constipation: Targeted Mechanisms to Maintain Pain Control Without Compromise
The content for this activity is based on the satellite symposium, Strategies for Combating Opioid-Induced Constipation: Targeted Mechanisms to Maintain Pain Control Without Compromise that was presented at the American Academy of Physical Medicine and Rehabilitation Annual Assembly (AAPM&R) on October 21, 2016. Opioid-induced constipation (OIC) is a common side effect of opioid use and can occur from the outset of opioid therapy. OIC has been reported to interfere with pain management, increase health care costs, decrease work productivity and daily activities, and significantly affect patient quality of life. It can also lead to bowel obstruction. Assessing and managing OIC is important for establishing maximum function for patients. Several pharmacologic approaches, with different mechanisms of action, are available or in development.
This activity has been designed to meet the educational needs of health care professionals responsible for chronic pain management.
Upon completion of this activity, participants will be better able to do the following:
- Summarize the burden of OIC
- Cite the mechanism of action of available pharmacotherapies used to treat OIC
- Develop a treatment plan for OIC based on the benefits and limitations of available pharmacotherapies
- Formulate a discussion plan designed to engage patients and caregivers in a dialogue about OIC symptoms and treatments
Michael J. Brennan, MD
Steven P. Stanos, DO
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Relationship Identified With:
Michael J. Brennan, MD
Consultant/Advisor: CARA Therapeutics; DAIICHI SANKYO COMPANY, LIMITED; Depomed, Inc.; Endo Pharmaceuticals Inc.; Purdue Pharma L.P.
Speakers’ Bureau: AstraZeneca; CARA Therapeutics; Depomed, Inc.; Endo Pharmaceuticals Inc.; Purdue Pharma L.P.
Stock Owner: CARA Therapeutics
Steven P. Stanos, DO
Consultant/Advisor: DAIICHI SANKYO COMPANY, LIMITED; Endo Pharmaceuticals Inc.; Matrix Healthcare Services, Inc.; Pfizer Inc.; Purdue Pharma L.P.; SCILEX Pharmaceuticals, Inc.
Non-faculty: Lyerka Miller, PhD; Linda Kitlinski; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This CME activity has been peer-reviewed by PM&R: The journal of injury, function and rehabilitation.
This activity has been supported by independent educational grants from AstraZeneca; Salix Pharmaceuticals, Inc; and Shionogi Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education; Miller Medical Communications, LLC; AstraZeneca; Salix Pharmaceuticals, Inc; and Shionogi Inc do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.50 AMA PRA Category 1 Credit(s)™
- 1.50 Non-physician